At September 30, 2025, Edesa had cash and cash equivalents of $10.8 million and working capital of $10.4 million. Subsequent to the fiscal year end, the company received $3.4 million in net proceeds, ...
Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...
A 2025 report from a bipartisan, congressionally chartered commission warns that China is closing in on a win, and the United ...
MarketBeat on MSN
2 small-cap biotechs that could reward patient investors
Speculative investors and patience rarely go hand in hand. Nevertheless, if you’re looking to invest in the small-cap biotech ...
A raging bull market for biotech stocks and a good story have transformed an ineffective weight loss drug into a Wall Street ...
In the northwest corner of Sioux Falls, an 80-acre campus opened its first building this year dedicated entirely to expanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback